Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Rheumatology International

Volumn 30, Issue 2, 2009, Pages 213-221

  Ringe, Johann D ^a   Möller, Gerd ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b AMGEN INC   (United States)

Author keywords

Adverse events; Branded bisphosphonates; Efficacy; Generic alendronate; Persistence; Risedronate

Indexed keywords

ALENDRONIC ACID; CALCIUM; GENERIC DRUG; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE PAIN; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EPIGASTRIC DISCOMFORT; EPIGASTRIC PAIN; ESOPHAGUS BURN; FEMALE; FRACTURE; HEADACHE; HIP; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METEORISM; MUSCLE CRAMP; NAUSEA; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERTEBRA FRACTURE; VOMITING;

ALENDRONATE; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; DRUGS, GENERIC; ETIDRONIC ACID; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; VITAMIN D;

EID: 71349084159     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-0940-5     Document Type: Article

References (55)

1. Dachverband Deutschsprachiger Wissenschaftlicher Gesellschaften für Osteologie (2006) DVO-guideline for prevention, clinical assesssment and treatment of osteoporosis for women after menopause, for men after age 60. http://www.lutherhaus.de/osteo/leitlinien-dvo/index.php
2. J Pfeilschifter 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60. Executive summary guidelines Exp Clin Endocrinol Diabetes 114 611 622 1:CAS:528: DC%2BD2sXms1GrtA%3D%3D 17252642
3. O Johnell JA Kanis 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726 1733 10.1007/s00198-006-0172-4 10.1007/s00198-006-0172-4 1:STN:280: DC%2BD28nitVSksQ%3D%3D 16983459 (Pubitemid 44607392)
4. A DeSantis A Buchman 2002 2002 current and emerging therapies in osteoporosis Expert Opin Pharmacother 3 835 843 10.1517/14656566.3.7.835 10.1517/14656566.3.7.835 1:CAS:528:DC%2BD38XlvVWisrs%3D 12083984 (Pubitemid 34752502)
5. K Kobayashi K Shimoyama K Nakamura K Murata 2005 Percutaneous vertebroplasty immediately relieves pain of osteoporotic vertebral compression fractures and prevents prolonged immobilization of patients Eur Radiol 15 360 367 10.1007/s00330-004-2549-0 10.1007/s00330-004-2549-0 15662480
6. DJ Theodorou SJ Theodorou DJ Sartoris 2002 Treatment of osteoporosis: current status and recent advances Compr Ther 28 109 122 10.1007/s12019-002- 0048-2 10.1007/s12019-002-0048-2 12085458
7. UA Liberman SR Weiss J Broll, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 10.1056/NEJM199511303332201 10.1056/NEJM199511303332201 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143
8. DM Black SR Cummings DB Karpf, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 10.1016/S0140-6736(96)07088-2 10.1016/S0140-6736(96)07088-2 1:CAS:528: DyaK2sXisFCktQ%3D%3D 8950879 (Pubitemid 26411651)
9. SR Cummings DM Black DE Thompson, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial JAMA 280 2077 2082 10.1001/jama.280.24.2077 10.1001/jama.280.24.2077 1:CAS:528:DyaK1MXjsVWruw%3D%3D 9875874 (Pubitemid 29014065)
10. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 10.1001/jama.282.14.1344 10.1001/jama.282.14.1344 1:CAS:528:DyaK1MXmvFansr0%3D 10527181 (Pubitemid 29483192)
11. J Reginster HW Minne OH Sorensen, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 10.1007/s001980050010 10.1007/s001980050010 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10663363 (Pubitemid 30099515)
12. JD Ringe H Faber P Farahmand, et al. 2006 Efficacy of risedronate in men with primary and secondary osteoporosis. Results of a 1-year study Rheumatol Int 26 427 431 10.1007/s00296-005-0004-4 10.1007/s00296-005-0004-4 1:CAS:528:DC%2BD28XhslOkt7s%3D 16001181 (Pubitemid 43318323)
13. CH Chesnut III A Skag C Christiansen, et al. 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249 10.1359/JBMR.040325 10.1359/JBMR.040325 1:CAS:528:DC%2BD2cXntFGqurw%3D (Pubitemid 41094364)
14. JD Ringe A Dorst H Faber, et al. 2003 Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative trial Osteoporos Int 14 801 807 10.1007/s00198-003-1425-0 10.1007/s00198-003-1425-0 1:CAS:528: DC%2BD3sXosFWrsLw%3D 14610641 (Pubitemid 37462129)
15. MR McClung P Geusens PD Miller, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 10.1056/NEJM200102013440503 10.1056/NEJM200102013440503 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 11172164 (Pubitemid 32107641)
16. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 10.1056/NEJMoa067312 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D 17476007 (Pubitemid 46698462)
17. SEIOMM. http://www.seiomm.org/
18. Nuova Nota 79 relativa all'osteoporosi. http://www.amiciitalia.org/nuovo- nota-79.htm
19. FH Ebetino BL Barnett RGG Russell 2005 A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonates in clinical use J Bone Miner Res 20 suppl 1 S259
20. RG Russell Z Xia JE Dunford U Oppermann A Kwaasi PA Hulley KL Kavanagh JT Triffitt MW Lundy RJ Phipps BL Barnett FP Coxon MJ Rogers NB Watts FH Ebetino 2007 Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy Ann N Y Acad Sci 1117 209 257 10.1196/annals.1402.089 10.1196/annals.1402.089 1:CAS:528:DC%2BD1cXhtVGmurY%3D 18056045 (Pubitemid 350191297)
21. Actonel® 5 mg Filmtabletten Fachinformation
22. C Roux E Seeman R Eastell J Adachi RD Jackson D Felsenberg S Songcharoen R Rizzoli O Di Munno S Horlait D Valent NB Watts 2004 Efficacy of risedronate on clinical vertebral fractures within 6 months Curr Med Res Opin 4 433 439 10.1185/030079903125003125 10.1185/030079903125003125 (Pubitemid 38525150)
23. JT Harrington LG Ste-Marie ML Brandi R Civitelli P Fardellone A Grauer I Barton S Boonen 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 2 129 135 10.1007/s00223-003-0042-4 10.1007/s00223-003-0042-4 1:CAS:528: DC%2BD2cXhtFGjt78%3D 14648009 (Pubitemid 38263854)
24. SL Silverman NB Watts PD Delmas, et al. 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 25 34 10.1007/s00198-006-0274-z 10.1007/s00198-006-0274-z 1:CAS:528:DC%2BD28Xht1OhtrfI 17106785 (Pubitemid 44885493)
25. JA Cramer MM Amonkar A Hebborn R Altman 2006 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 10.1185/030079905X61875 10.1185/030079905X61875
26. JJ Caro KJ Ishak KF Huybrechts, et al. 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 10.1007/s00198-004-1652-z 10.1007/s00198-004-1652-z 15167989 (Pubitemid 40064656)
27. Sebaldt RJ et al (2004) Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. Annual European Congress of Rheumatology "EULAR 2004"
28. ES Siris ST Harris CJ Rosen, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases Mayo Clin Proc 81 8 1013 1022 10.4065/81.8.1013 16901023
29. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf PK Wong 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359
30. Papaioannou A, Ioannidis G, Grima D, Adachi JD (2008) Quantification and description of gastrointestinal adverse events (GI AES) in patients switched from branded Fosamax® to generic alendronate. http://www.iscd.org/Visitors/ pdfs/ISCD-abstracts.pdf. Abstract #152
31. Actonel® einmal wöchentlich 35 mg Filmtabletten Fachinformation Januar 2003
32. Fosamax® 10 mg Fachinformation Fachinformation Februar 2002
33. Fosamax® einmal wöchentlich 70 mg Tabletten Fachinformation (Zusammenfassung der Merkmale des Arzneimittels, SPC) Mai 2002
34. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 10.1016/j.bone.2005.10.022 10.1016/j.bone.2005.10.022 16330270 (Pubitemid 44498580)
35. D Weycker D Macarios J Edelsberg G Oster 2007 Compliance with osteoporosis drug therapy and risk fracture Osteoporos Int 18 271 277 10.1007/s00198-006-0230-y 10.1007/s00198-006-0230-y 1:STN:280: DC%2BD2s%2FoslKktg%3D%3D 17021945 (Pubitemid 46233172)
36. JS McCombs P Thiebaud C Laughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 10.1016/j.maturitas.2004.02.005 10.1016/j.maturitas.2004.02.005 1:CAS:528:DC%2BD2cXltVCiu7g%3D 15207894 (Pubitemid 38781153)
37. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 10.4065/81.8.1013 16901023
38. FJ Penning-van Beest JA Erkens M Olson RM Herings 2008 Loss of treatment benefit due to low compliance with bisphosphonate therapy Osteoporos Int 19 511 517 10.1007/s00198-007-0466-1 10.1007/s00198-007-0466-1 1:STN:280: DC%2BD1c7nvFWqtw%3D%3D 17874028
39. H Taggart MA Bolognese R Lindsay MP Ettinger H Mulder RG Josse A Roberts H Zippel S Adami TF Ernst KP Stevens 2002 Upper gastrointestinal tract safety of risedronate: a pooled analysis of nine clinical trials Mayo Clin Proc 77 3 262 270 10.4065/77.3.262 1:CAS:528:DC%2BD38Xit1ans7w%3D 11888030
40. DD Mellström OH Sörensen S Goemaere C Roux TD Johnson AA Chines 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 6 462 468 10.1007/s00223-004-0286-7 15455188 (Pubitemid 40174503)
41. S Adami K Pavelka GA Cline MA Hosterman IP Barton SB Cohen WG Bensen 2005 Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial Mayo Clin Proc 80 10 1278 1285 10.4065/80.10.1278 1:CAS:528:DC%2BD2MXhtFeltrfI 16212139
42. NB Watts K Worley A Solis J Doyle R Sheer 2004 Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database J Manag Care Pharm 10 2 142 151 15032563
43. FL Lanza RH Hunt AB Thomson JM Provenza MA Blank 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterology 119 631 638 10.1053/gast.2000.16517 10.1053/gast.2000.16517 1:CAS:528:DC%2BD3cXmslSku7Y%3D 10982755
44. AB Thomson JK Marshall RH Hunt JM Provenza FL Lanza MG Royer Z Li MA Blank Risedronate Endoscopy Study Group 2002 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status J Rheumatol 29 9 1965 1974 1:CAS:528:DC%2BD38Xns1aksbs%3D 12233894
45. JD Adachi S Adami PD Miller WP Olszynski DL Kendler SL Silverman AA Licata Z Li E Gomez-Panzani 2001 Tolerability of risedronate in postmenopausal women intolerant of alendronate Aging (Milano) 13 5 347 354 1:CAS:528: DC%2BD38Xhs1eltrc%3D
46. PC deGroen DF Lubbe LJ Hirsch, et al. 1996 Esophagitis associated with the use of alendronate N Engl J Med 335 1016 1021 10.1056/NEJM199610033351403 10.1056/NEJM199610033351403 1:STN:280:DyaK28zmvFGrtQ%3D%3D (Pubitemid 26338731)
47. RJ Dansereau DJ Crail AC Perkins 2008 In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications Curr Med Res Opin 24 1137 1145 10.1185/030079908X280725 10.1185/030079908X280725 1:CAS:528:DC%2BD1cXmsVWgurw%3D 18334082 (Pubitemid 351579172)
48. AC Perkins PE Blackshaw PD Hay SC Lawes CT Atherton RJ Dansereau LK Wagner DJ Schnell 2008 Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single blind, si-period crossover study in healthy female subjects Clin Ther 30 834 844 10.1016/j.clinthera.2008.04.018 10.1016/j.clinthera.2008.04.018 1:CAS:528:DC%2BD1cXhtValsr3J 18555931 (Pubitemid 351799865)
49. S Epstein P Geusens JE Fisher, et al. 2005 Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy J Appl Res 5 253 264 1:CAS:528:DC%2BD2MXnslyhs7o%3D
50. S Epstein B Cryer S Gagi, et al. 2003 Disintegration/dissolution profiles of copies of fosamax (alendronate) Curr Med Res Opin 19 781 789 10.1185/030079903125002577 10.1185/030079903125002577 1:STN:280: DC%2BD3sngsFWmug%3D%3D 14687450 (Pubitemid 37466149)
51. JH Lin 1996 Bisphosphonates: a review of their pharmacokinetic properties Bone 18 75 85 10.1016/8756-3282(95)00445-9 10.1016/8756-3282(95)00445-9 1:CAS:528:DyaK28XisVGjs7g%3D 8833200 (Pubitemid 26092586)
52. Fleisch H (2000) Bisphosphonates in bone disease: from the laboratory to the patient. Academic Press, New York. ISBN: 0-12-260370-2. 2.4 Pharmacokinetics, pp 56-62
53. DA Grimes KF Schulz 2002 Bias and causal associations in observational research Lancet 359 248 252 10.1016/S0140-6736(02)07451-2 10.1016/S0140-6736(02) 07451-2 11812579 (Pubitemid 34113828)
54. N Black 1996 Why we need observational studies to evaluate the effectiveness of health care BMJ 312 1215 1218 1:STN:280:DyaK283hsVGluw%3D%3D 8634569
55. R Dowd RR Recker RP Heaney 2000 Study subjects and ordinary patients Osteoporos Int 11 533 536 10.1007/s001980070097 10.1007/s001980070097 1:STN:280:DC%2BD3cvotFShtw%3D%3D 10982170 (Pubitemid 30681652)